Proteinase-activated receptor 2 (PAR 2 ) is a G protein-coupled receptor involved in metabolism, inflammation, and cancers. It is activated by proteolysis, which exposes a nascent N-terminal sequence that becomes a tethered agonist. Short synthetic peptides corresponding to this sequence also activate PAR 2 , while small organic molecules show promising PAR 2 antagonism. Developing PAR 2 ligands into pharmaceuticals is hindered by a lack of knowledge of how synthetic ligands interact with and differentially modulate PAR 2 . Guided by PAR 2 homology modeling and ligand docking based on bovine rhodopsin, followed by cross-checking with newer PAR 2 models based on ORL-1 and PAR 1 , site-directed mutagenesis of PAR 2 was used to investigate the pharmacology of three agonists (two synthetic agonists and trypsin-exposed tethered ligand) and one antagonist for modulation of PAR 2 signaling. Effects of 28 PAR 2 mutations were examined for PAR 2 -mediated calcium mobilization and key mutants were selected for measuring ligand binding. Nineteen of twenty-eight PAR 2 mutations reduced the potency of at least one ligand by >10-fold. Key residues mapped predominantly to a cluster in the transmembrane (TM) domains of PAR 2 , differentially influence intracellular Ca 2+ induced by synthetic agonists versus a native agonist, and highlight subtly different TM residues involved in receptor activation. This is the first evidence highlighting the importance of the PAR 2 TM regions for receptor activation by synthetic PAR 2 agonists and antagonists. The trypsin-cleaved N-terminus that activates PAR 2 was unaffected by residues that affected synthetic peptides, challenging the widespread practice of substituting peptides for proteases to characterize PAR 2 physiology. © 2017 Elsevier Ltd. All rights reserved.
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Introduction
Proteinase-activated receptors are unique G protein-coupled receptors (GPCRs) in being self-activated following proteolytic action at their extracellular N-terminus by mainly serine proteases [1, 21, 20] . This exposes a new N-terminus, the 'tethered ligand', which folds back and binds intramolecularly to induce intracellular signaling via poorly understood mechanisms [9, 52] . Four PARs have been identified and numbered in order of their discovery [19] . PAR 2 is activated by serine proteases such as trypsin and tryptase but, unlike other PARs, not by thrombin [1, 3, 7, 11, 50] . PAR 2 can also be activated by synthetic peptide agonists that mimic the N-terminal sequence of the tethered ligand e.g. SLIGRL-NH 2 (rodent), SLIGKV-NH 2 (human), 2f-LIGRLO-NH 2 (potent derivative), P2-Pal-21F and 2at-LIGRL-PEG3-hdc (both lipid-tethered derivatives) [7, 31, 43, 55, 27, 13] and by small molecule agonists (e.g. AC-55541, AC-264613 [54] ). Our group has identified two non-peptide ligands that were selective for PAR 2 over PAR 1 and other GPCRs, the agonist GB110 and antagonist GB88 [8, 57, 58] . GB110 had identical agonist potency with 2f-LIGRLO-NH 2 in inducing Ca 2+ release in multiple cell types. In addition, both GB110 and 2f-LIGRLO-NH 2, as well as proteases like trypsin and tryptase but not thrombin, were inhibited by PAR 2 antagonist GB88. In recent years PAR 2 has been implicated in many in vitro and in vivo models of inflammatory diseases as well as cancer and metabolic disorders [1, 3, 5, 12, 38, 50, 56, 62, 66] . The PAR 2 -selective antagonist GB88 has shown beneficial effects in vivo in rodent models of inflammation including paw odema [57, 58] , collagen-induced arthritis [39] , experimental colitis [40] and diet-induced obesity [37] .
Ligand interactions with PAR 2 have previously been reported to involve the extracellular N-terminus and extracellular loop 2 (ECL2) [4, 15, 16, 42] . A common polymorphism at position 240 potentiates PAR 2 activation by certain ligands, but not others [15, 42] . Also, sitedirected mutagenesis indicated that by removing the glycosylation site of rat PAR 2 ECL2 by mutating N222A reduced sensitivity to both trypsin and PAR 2 activating peptide [16] . Mutations at positions 231-233 reportedly reduce agonist potency by ≤100-fold [4] . Each of these studies focused on the ECLs but did not examine a role for residues within the transmembrane (TM) domains of PAR 2 .
As crystal structures for class A GPCRs human A2A, turkey ␤1 and human P2Y 12 [63, 65, 68] show extensive interactions between a bound agonist and residues in TM regions, we hypothesized that the TM regions of PAR 2 are important in influencing ligand-induced receptor activation. Based on a homology structural model of PAR 2 ( Fig. 1) derived by sequence alignment with a crystallographically characterized GPCR, 28 PAR 2 mutants were constructed to investigate whether specific amino acids in the receptor affected PAR 2 activation by endogenous (trypsin induced) and synthetic agonists (2f-LIGRLO-NH 2 and GB110). 2f-LIGRLO-NH 2 was selected as the most commonly used peptide agonist for PAR 2 , while GB110 was selected as a potent non-peptidic agonist and we have previously studied this agonist in detail [57] . We also selected antagonist GB88 due to its reported antagonist properties both in vitro and in vivo [57, 39] . The effect of each PAR 2 mutation on ligand-induced downstream signaling was assessed to elucidate the impact of these residues on PAR 2 activation. Herein, a cluster or 'hot spot' of receptor residues that affect the activation of PAR 2 by the tested ligands has been identified. Whether other structurally diverse PAR 2 agonists or antagonists are affected by similar 'hot spot' residues remains to be determined, but this study provides valuable new insights for rational design of future PAR 2 agonists and antagonists. These prospective drugs might be used to selectively modulate PAR 2 -mediated signaling and influence the pathophysiological function of PAR 2 in disease.
Methods
2.1. Sequence alignment of human PAR 2 with bovine rhodopsin crystal structure (pdb: 1U19) and homology modeling
The human PAR 2 sequence obtained from Swiss-Prot (accession number P55085) was aligned with the bovine rhodopsin crystal structure (pdb: 1U19, monomer) sequence using the PAM-250 matrix, which aligns the sequence based on conservation of charged, bulky aliphatic, or aromatic residues. Alignment was refined manually by examining structurally conserved regions and assessing likely TM regions using a reported approach [9] . The seven TM helices were identified based on conserved residues in each putative TM helix. The alignment was used to develop coordinates for TM regions using Modeller TM , with a disulfide bond constraint between C148 (TM3) and C226 (ECL2). Loop regions were developed using Modeller TM and the rhodopsin template. The model was refined to remove steric clashes by a minor modification of the minimisation and molecular dynamics protocol above (the Newton minimisation algorithm was not performed because of the large number of atoms). In this minimisation protocol, TM backbone atoms were kept tethered to maintain TM helicity. The resulting conformation was used for ligand docking.
2.2.
Homology modeling based on nociceptin/orphanin FQ/ORL-1 receptor (pdb: 4EA3, TM sequence identity = 29%) and PAR 1 (pdb: 3VW7, TM sequence identity = 44%)
Modeller 9v10 [53] was used to build homology models of PAR 2 based on ORL-1 and PAR 1 crystal structures, after aligning the PAR 2 sequence with the templates using Jalview [64] . The models with the lowest discrete optimization protein energy (DOPE) score were further optimized for the ECL2 loop refinement in Prime (version 3.1, Schrödinger, LLC, New York, NY, 2012) using the truncated-Newton energy minimization (OPLS 2005 force field with restrained helical backbone). The final models were refined using the protein preparation wizard in Schrödinger to optimize hydrogen bond networks and for a restrained energy minimization (OPLS 2005 force field and heavy atom movement <0.5 Å).
Ligand docking
All ligands were constructed in 2D sdf format using ChemDraw. Conversion from 2D into 3D co-ordinates was performed using LigPrep in Maestro (Schrödinger). OPLS (Optimized Potentials for Liquid Simulations) force field was applied during ligand structural optimization and the protonation status of ligands was set for physiological conditions. Ligand docking was performed using GOLD (ccdc v3.2) with default docking settings. GOLD applies a genetic algorithm during docking simulation and each ligand conformation is encoded analogously as evolution of a population of possible solutions via genetic operators to a final population. A radius of 10 Å around residue F300 or F6.48 (Ballesteros Weinstein numbering scheme) [6] was defined as the putative ligand-binding site. Ligands were docked in 10 independent poses (population size 100). Operator weights for mutations, migration and crossover were 95, 10 and 95 respectively. To account for partial flexibility of PAR 2 , residues (F243, F155, F300, Y156, M159, L307, L330, D228, F251, L246) were defined and allowed to move according to the Chi rotamer library developed in the docking run [41] . Docked poses were ranked using the internal Gold score [32] and manual inspection of interactions with receptor. Final analysis and visualisation of protein-ligand interactions were performed using Pymol. To crosscheck the results from the Rhodopsin-derived PAR 2 model, the ligands were also subsequently docked into PAR 2 homology models built from ORL-1 and PAR 1 crystal structures. The PAR 2 homology structures and ligand docking protocols using these models are detailed elsewhere [71] .
Cell culture and reagents
Cell culture reagents were purchased from Invitrogen (Carlsbad, CA) and Sigma Aldrich (St. Louis, MO). Flp-In Chinese Hamster Ovary (CHO)-K1 cells (Invitrogen) were maintained in Ham's F12 media containing 10% FBS and 2 mM l-glutamine in 5% CO 2 at 37 • C. PAR 2 peptide agonist (2f-LIGRLO-NH 2 ), non-peptide agonist (GB110) and non-peptide antagonist (GB88) were synthesized inhouse [8] . A23187 was purchased from Sigma-Aldrich, Fluo-3 AM and Pluronic F127 from Sapphire Bioscience (NSW, Australia), and assay plates from Corning (New York, NY). 
n = number of independent experiments. pEC50 = −log(EC50). pEC50 ± S.D., Fold Change = EC50 Mutant/EC50 Wild Type.
Vector construction and transfection
cDNA encoding human PAR 2 with a C-terminal FLAG epitope (DYKDDDDK) was subcloned into a pcDNA5/FRT vector (Life technologies/invitrogen) using a BamHI restriction enzyme site. Site directed mutagenesis was performed using a QuickChange kit (Stratagene) according to manufacturer's instructions to generate individual receptor mutants (Table 1) . Primer sequences are available upon request. All constructs were sequenced at the Australian Genomic Research Facility (St Lucia, Australia). Stably expressing cells were generated following manufacturer's instructions. PAR 2 -pcDNA5/FRT constructs were cotransfected with Flp-recombinase expression vector pOG44 (1:9 pcDNA5/FRT:pOG44) into Flp-In CHO-K1 cells using Lipofectamine 2000. Stable polyclonal populations of transfected cells were selected in media containing 600 g/mL hygromycin B.
Crude membrane preparation and Western blot analysis
Expression of wildtype and each PAR 2 mutant was assessed as described [2, 3] . Crude membrane preparations were collected by isotonic cell shock and mechanical disruption followed by ultracentrifugation (100,000g for 60 min at 4 • C) to pellet the membrane fraction. Fractions were resuspended in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100 (v/v) and 1 × protease inhibitor cocktail (Roche)) before quantification using a BCA assay kit from Pierce (Thermo Fisher Scientific, Scoresby, Australia). Equal amounts of membrane fractions were separated by SDS-PAGE and transferred to nitrocellulose membrane. Membranes blocked in Odyssey blocking solution from LiCor (Millennium Science, Surrey Hills, Australia) were incubated with goat anti-PAR 2 N19 (Santa Cruz, Dallas, U.S.A.) and mouse anti-Pan Cadherin (Millipore) antibodies overnight at 4 • C. Membranes were washed and incubated with species appropriate IRdye 700 or 800 secondary antibodies at ambient temperature for 45 min before washing to minimize non-specific signals followed by scanning on an Odyssey infrared imaging system (LiCor).
Flow cytometry analysis
Cell surface expression of wildtype and each PAR 2 mutant was assessed as described [2] . Cells (2.5 × 10 5 ) dissociated nonenzymatically from cell culture flasks were washed and stained with goat anti-PAR 2 N19 antibody (2 g/1 × 10 6 cells) in buffer (2% BSA in PBS) for 30 min at 4 • C. Cells were washed and stained with AlexaFluor 488-conjugated donkey anti-goat secondary antibody before analysis on a Beckman Coulter FC500 flow cytometer. Events were counted (20,000) and mean fluorescence intensity (MFI) was used to assess cell surface PAR 2 after subtracting MFI values from cells incubated only with secondary antibody. Competitive ligand binding and calcium mobilization assays are well established methods reported in Supporting Material.
Competitive binding assay
Assays were performed as described [29] . Cells were seeded overnight in a 384-well plate at a density of 24,000 cells per well. On the day of experiment, media was aspirated and cells were washed with PBS followed by 2% BSA blocking for 1 h at 37 • C. After blocking, cells were simultaneously exposed to concentrations of 2f-LIGRLO(dtpa)-NH 2 and 2f-LIGRLO-NH 2 (100 M) for 15 min. Cells were washed thrice with PBS supplemented with 20 M EDTA, 0.01% Tween and 0.2% BSA. After washings, cells were incubated with 40 l of DELFIA enhancement solution (Perkin Elmer) for 90 min. Fluorescence was determined with TRF analysis (Pherastar FS, BMG Labtech): 340 nm excitation followed by 400 s delay before a 400 s 615 nm emission.
Intracellular calcium mobilization
Cells were grown to 80% confluence. Prior to experiment, cells were seeded overnight in 96-well black wall, clear bottom, plates at ∼5 × 10 4 cells per well. On the day of the experiment, supernatant was removed and cells were incubated in dye loading buffer (Hank's Balanced Salt Solution (HBSS) with 4 M Fluo-3, 0.04% pluronic acid, 1% fetal bovine serum (FBS) and 2.5 mM probenecid) for 1 h at 37 • C. Cells were washed twice with HBSS and transferred to a FLIPR Tetra plate reader (Molecular Device, Sunnyvale CA) for agonist injection and fluorescence measurements. PAR 2 agonists were added 10 s after reading commenced at various concentrations and fluorescence was measured in real time using excitation 480 nm and emission 520 nm. HBSS was prepared in-house, all other reagents were from Invitrogen (Carlsbad), plates from Corning. Calcimycin (A23187, Sigma Aldrich) was used to measure maximum fluorescence, with individual results normalized accordingly.
Statistical analysis
Data were analyzed in GraphPad Prism (GraphPad Software, San Diego, CA) using ANOVA or Student's t-test with values as mean ± SEM (n ≥ 3). Data are presented as the mean of the entire data set. Significance was determined by P < 0.05. When plotted in concentration-response curve, intracellular Ca 2+ response was normalized against the highest concentration of respective agonist in CHO-hPAR 2 WT. Concentration-response curves were fitted in GraphPad Prism with a standard Hill slope of 1 (three-parameter fit).
Results

Homology structural models of PAR 2
A PAR 2 structural homology model was first generated by sequence alignment of human PAR 2 to the crystal structure of bovine rhodopsin (pdb: 1U19; [47] . The PAR 2 homology model was submitted to the SwissModel portal (http://swissmodel.expasy. org/) for quality and stereochemical properties checks. The assessment of model quality-related parameters (such as Qmean6 score, dfire energy and Ramachandran statistics) were compared with the original crystal structure for bovine rhodopsin (1U19). The PAR 2 homology model gave a RMSD value of 0.37Å compared to the bovine rhodopsin. Qmean6 score (PAR 2 0.41, Rhodopsin 0.40) is a linear combination of six structural descriptors and a higher Qmean6 (range between 0 and 1) reflects strong reliability of the model. DFire (PAR 2 -465.5; Rhodopsin -557.8) is an all-atom statistical potential term used to assess non-bonded atomic interactions in the protein model. The homology model of PAR 2 produced comparable scores for these two components, relative to the template from which they were constructed. Furthermore, all residues in the rhodopsin based homology model were located in the favored and allowed ϕ-regions from the Ramachandran plot analysis, suggesting that the constructed homology model was both energetically and stereochemically reliable.
In silico docking of three ligands in a PAR 2 homology structural model
Interactions between PAR 2 and three synthetic ligands were examined in silico (Fig. 1A) . Synthetic ligands used in silico were the two PAR 2 agonists, 2f-LIGRLO-NH 2 [33, 44] and GB110 [8] , as well as the PAR 2 antagonist GB88 [57] (Fig. 1B-D) . All three ligands were also experimentally assessed in an intracellular calcium mobilization assay.
Modeling predicted that both agonists would occupy a similar binding region within the TM domains of PAR 2 . 2f-LIGRL-NH 2 rather than 2f-LIGRLO-NH 2 was docked since the ornithine does not contribute significantly to agonist potency and can confound docking orientations due to its charged sidechain finding alternative binding sites on its own [33, 44] . The similar components of 2f-LIGRL-NH 2 and GB110 (2-furoyl vs isoxazole, Leu vs Cha, Ile vs Ile) were predicted to dock into pockets formed by TM3 (Y156, Y160), TM5 (F243, L246, V250) and TM6 (N304, L307, V308) (Fig. 1B,C) . The other ligand components were predicted to orient slightly differently for the two agonists. R4 in 2f-LIGRL-NH 2 was predicted to orient towards residues at the top of TM6 (Y311) and TM7 (Y326) as well as ECL2 (D228) (Fig. 1B) . However, the terminal aminomethyl piperidine group of GB110 was predicted to project between TM2 (Y82) and TM7 (L330) (Fig. 1C) . The antagonist GB88 docked in a similar binding site, but its orientation was reversed with the isoxazole in a small pocket formed by Y82, F155 and L330 (Fig. 1D) . Its cyclohexylalanine oriented into space between TM6 (Y307) and TM7 (Y326), while isoleucine oriented towards F155. The bulky spiroindenepiperidine occupied a hydrophobic site surrounded by Y156, Y160, F243, F251 and N304 (Fig. 1D ). These predicted sites suggested a cluster of amino acids within the TM regions of PAR 2 that might be expected to influence ligand binding potencies and efficacies.
We also constructed homology models of PAR 2 against alternative templates using the crystal structures of the human nociceptin/orphan FQ receptor (4EA3) [60] and the antagonist bound PAR 1 receptor (3VW7) [67] to verify the bovine rhodopsin homology model. When the above ligands were docked into either of these new models of PAR 2 based on the different template crystal structures, the key residues inferred from the rhodopsinbased model of PAR 2 (Y82, L151, F155, Y156, F243, L307, Y311, Y326, L330) were also found in the ORL-1 derived model of PAR 2 , while Y156, Y160, E232, F243, L307, Y311, Y326, L330 were also found in the PAR 1 -based model of PAR 2 . In particular, both models predicted 2f-LIGRL-NH 2 to make several polar interactions with residues Y311, D228 ECL2 , whereas Y156 from the ORL-1 model was also predicted to form a polar contact with the ligand. The rest of the residues were mainly predicted to contribute to hydrophobic and aromatic interactions. The major difference seen was the position of the 2f group, which was docked within a pocket between TM2 and TM7 in the ORL-1 based model, while in the PAR1 based model this group was docked between TM5 and TM6 [71] . Of the residues shown ahead to cause >30-fold reduction in receptor activation, only Y296 and N304 were not predicted from the new homology models of PAR 2 . Interestingly, those two residues are the deepest in the TM 7-helix bundle and might be indirectly impacted through knock-on or conformational changes during receptor activation. The new models of PAR 2 thus supported the above predictions based on the bovine rhodopsin derived PAR 2 homology structure, while presenting some new clues for further refinement of the PAR 2 model.
Based on the ligand-binding sites predicted from rhodopsin, 18 PAR 2 TM residues (Y82, F128, L151, F155, Y156, Y160, F243, L246, V250, F251, Y296, S303, N304, L307, Y308, Y311, Y326, L330) and an ECL2 residue (D228) were chosen for mutagenesis to investigate the experimental effect of these mutations on ligand-induced downstream signaling. Two additional ECL2 residues, E232 and Q233, were also selected for mutation on the basis of previous studies [4] , giving a total of 21 amino acids to be mutated. Fig. 1 displays these residues revealing where they cluster within or near the TM regions of PAR 2 , thereby forming putative 'hot spots' in PAR 2 that might dictate agonist and antagonist ligand activity.
Mutation of PAR 2 in stably expressing cell lines
Site directed mutagenesis generated expression constructs encoding the relevant amino acid mutated to alanine (Y82, L151,  D228, E232, Q233, F243, L246, V250, F251, Y296, S303, L307,  Y308) , chosen to inform the importance of larger sidechains for space-filling; to leucine (Y160) or tryptophan (L330) to test the importance of aromaticity; or with 6 residues mutated to both small alanine and bulkier hydrophobic leucine (F128, F155, Y156 , N304, Y311, Y326). A construct encoding the double mutant E322A/Q233A was also generated to allow comparison with a previous study on rat PAR 2 [4] to give a total of 28 PAR 2 mutant expression constructs. To examine the impact of these mutations on ligand-induced signaling, CHO-K1 cells were generated that stably expressed each of the 28 mutants or wildtype PAR 2 . The impact of each mutation on structural integrity of PAR 2 and its cell surface expression was assessed using Western blot and flow cytometry. Western blot analysis revealed that each PAR 2 was expressed at consistent levels as a characteristic ladder of bands from ∼30-80 kDa ( Fig. 2A, upper panel) , as described [2] . Similarly, flow cytometry demonstrated that cell surface expression was comparable for wildtype and each mutant PAR 2 ( Fig. 2A, lower panel) . These data indicated structurally integrity and PAR 2 surface expression on CHO-K1 cells. Importantly, cells transfected with vector failed to produce any significant signal in response to synthetic agonists 2f-LIGRLO-NH 2 and GB110 or tethered ligand formed by trypsin cleavage, in contrast to cells transfected with wildtype PAR 2 ( Fig. 2B-D) . This indicates that calcium mobilization in transfected cells was PAR 2 mediated.
Effect of PAR 2 mutations on synthetic agonist potencies
The impact of the PAR 2 mutations on receptor-mediated signaling was experimentally assessed by intracellular calcium release induced by escalating doses of 2f-LIGRLO-NH 2 or GB110. The pEC 50 and fold changes relative to wildtype PAR 2 are shown in Table 1 . Four mutations induced enormous reductions (>100 fold) in ligand potencies, three located in the TM domains (Y82A, Y156A, Y326A) and the fourth in ECL2 (D228A) ( Table 1 ). All four mutations had similar effects on potency of both agonists 2f-LIGRLO-NH 2 and GB110 (Fig. 3A-D) . Six other TM mutations (Y156L, F251A, Y296A, N304A, N304L, Y311A) along with ECL2 mutation E232A also induced substantial (>10 fold) reductions in signaling by both agonists (Table 1) . Overall, 19 of 28 mutant PAR 2 cell lines revealed ≥10 fold attenuation in activity for at least one agonist (Fig. 3E) . When analyzed by scatter plot, there was a high correlation between mutation-induced fold changes in activity of 2f-LIGRLO-NH 2 versus GB110 (Fig. 3F) , indicating that these ligands were affected by a similar set of residues of PAR 2 residues.
CHO cells stably transfected with vector only, or cells stably expressing either wild type PAR 2, or one of the eight mutant forms of PAR 2, were selected for measuring agonist affinity. Y156A, D228A and Y326A were chosen due to their significant impact on PAR 2 -induced calcium release (Table 1) . Five neighboring mutants (F155A, Y156L, Y160L, Y326L, L330W) were also selected. A receptor saturation assay was used to calculate K d for 2f-LIGRLO(dtpa)-NH 2 on each cell line (Fig. 4) . Control experiments with PAR 2 WT gave K d 0.67 M and the tagged peptide failed to bind to CHO cells not expressing PAR 2 . This suggested specific binding to human PAR 2 . Similar to the negative control, Y156A, D228A and Y326A all failed to give any measurable saturation, indicating that labeled peptide was not able to selectively bind to the mutated receptor expressed. In contrast, each of the remaining 5 mutants was able to produce a K d ∼3-5 fold weaker than wild type.
Effects of PAR 2 mutations on trypsin potency
The agonist potency was also measured for trypsin on the same 28 mutated PAR 2 transfected CHO cell lines in Table 1 . Only four mutations (Y82A, Y296A, N304A, N304L) caused >10-fold reductions in agonist potencies (Fig. 5A-C ) and all were in the TM regions of PAR 2 , indicating the importance of the TM regions in protease-mediated PAR 2 activation. However, in contrast to the two synthetic agonists, most mutations examined induced <10-fold reductions in trypsin-induced agonist potency (Fig. 5D ). This indicated that the tethered ligand was not as susceptible to the same mutations as the two synthetic agonists. In support of this conclusion, there was no significant correlation between effects of mutants on calcium mobilization induced by trypsin vs by each synthetic agonist (Fig. 5E,F) .
Effects of PAR 2 mutation on antagonist potency
GB88 is a small molecule reported to effectively antagonize calcium release in human cells by all PAR 2 agonists, including the peptides SLIGRL-NH 2 , SLIGKV-NH 2 , 2f-LIGRLO-NH 2 , the peptidomimetic GB110, and proteases like trypsin, tryptase and cathepsin S [8, 57, 69] . In order to determine the impact of mutation of PAR 2 residues on GB88 potency, cells were first incubated with escalating doses of GB88 and stimulated with trypsin at EC 80 determined from Table 1 . The pIC 50 and fold change (mutant versus wildtype PAR 2 ) values are listed in Table 2 . GB88 could not be tested against CHO-hPAR 2 Y82A cells, as the agonist response generated by trypsin was too small to produce a significant signal-to-noise ratio. Overall, seven mutants derived from changes at 5 positions (Y156, D228, N304, L307, Y326) on PAR 2 were found to inactivate GB88 (<40% max inhibition) antagonism of trypsin-induced intracellular calcium release (Fig. 6 ). In addition, L151A and F243A mutations reduced potency of GB88 by greater than 10-fold ( Table 2) .
Analysis of the effect of increasing concentrations of GB88 on Ca 2+ release, induced by escalating doses of 2f-LIGRLO-NH 2 and GB110, revealed that on CHO-hPAR 2 WT, GB88 caused a rightward horizontal shift of agonist concentration-response curves (Fig. 7A,B) and by Schild plots, which had linear slopes of 0.95 ± 0.1 and 1.15 ± 0.14 respectively (Fig. 7C,D) . Slight reductions of the maxima were also observed. The horizontal shift and reduction of maxima could be caused by the short assay timeframe, preventing the system to reach true equilibrium and leads to subsequent depression of maxima. Incubation time was reduced in order to investigate potential kinetic artefacts [14, 36] , however, GB88 was inactive against both 2f-LIGRLO-NH 2 and GB110 in the iCa 2+ assay without pre-incubation (Fig. 8A,B) . Furthermore, reduction of incubation time from 30 min to 5 min failed to recover the maxima (Fig. 8C,D) .
As mentioned earlier, most of the mutations caused a similar potency reduction for each of the two synthetic agonists, with the exception of F155A, V250A and L307A. These three mutants reduced GB110 potency to a much greater extent (10-, 17-and 54-fold respectively) than did 2f-LIGRLO-NH 2 (3-, 2-and 4-fold respectively). These differences in potency reductions suggested subtly different interactions between the two synthetic ligands and PAR 2 , so we similarly inspected corresponding effects on the antagonist GB88. As L307A was ruled out due to its inactivation of the antagonist (Table 2 , max inhibition 25%), further experiments were performed on the remaining two mutants (F155A, V250A). When IC 50 values of GB88 were calculated by increasing its concentration against a fixed agonist concentration, no significant difference was observed against each of the 2 agonists in each of the 3 cell lines (WT, F155A, V250A) (Fig. 9A, B) . However, as shown in Fig. 10 this was not true when a Schild plot analysis was performed. F155A showed similar results as wild type-PAR 2 for antagonism by GB88 against the two synthetic agonists, i.e. increasing concentrations of GB88 resulted in horizontal shifts in concentration-response curves of both 2f-LIGRLO-NH 2 (Fig. 9C) and GB110 (Fig. 9D) . In contrast to WT and F155A, V250A showed distinct differences in affecting each synthetic agonist. When GB88 was used to inhibit 2f-LIGRLO-NH 2 , reduction of maxima was significantly greater at >1 M (Fig. 9E) , whereas a similar maxima reduction was not observed when GB110 was used as agonist (Fig. 9F ). This indicated that the V250A mutation turned GB88 into an insurmountable antagonist against 2f-LIGRLO-NH 2 , but not against GB110. Schild slope analysis further validated the differences between F155A and V250A. F155A produced a linear gradient of 0.81 ± 0.1 for 2f-LIGRLO-NH 2 and 0.96 ± 0.1 for GB110, indicating GB88 is a competitive antagonist against both synthetic agonists in F155A PAR 2 (Fig. 9G) . In comparison, V250A produced steeper Schild slopes of 1.3 ± 0.1 (2f-LIGRLO-NH 2 ) and 1.6 ± 0.1 (GB110) (Fig. 9H) . A Schild slope >1 can indicate insufficient equilibration time, and GB88 may not have attained equilibrium at lower concentrations, thus changing the gradient of the Schild plot. A steep slope can also imply binding cooperativity of an antagonist, where the V250A mutation enables binding of more than one molecule of GB88. In either case, V250A mutation significantly changed how the receptor interacts with the agonist/antagonist. F155A also reduced the pA 2 of GB88 against 2f-LIGRLO-NH 2 from 6.2 (wild type) to 5.8, but the pA 2 value of GB88 against GB110 remained unchanged at 6.5, while V250A had no significant changes in pA 2 of GB88 against both agonists.
Discussion and conclusions
This is the first detailed analysis of the importance of amino acids in the transmembrane region of PAR 2 for dictating intracellular Ca 2+ release induced by PAR 2 ligands. This study monitored effects of PAR 2 mutations on calcium release, a signaling pathway commonly used for PAR 2 research and previously shown to dictate inflammatory responses of PAR 2 agonists 2f-LIGRLO-NH 2 , GB110, trypsin and the pathway selective anti-inflammatory antagonist GB88, both in vitro and in vivo in rodents [57, 58, 59] . This approach was used rather than a competitive binding assay for comparative ligand affinities for PAR 2 because, unlike other GPCRs, there is no orthosteric ligand for PAR 2 that can be used exogenously to compete with, since only proteases are known to endogenously activate PAR 2 . Thus, in order to correlate receptor binding with receptor activity, we instead performed a receptor saturation assay using 2f-LIGRLO(dtpa)-NH 2 on PAR 2 . Ten cell lines (WT, Vector, 8 mutants) were found to change the observed K d values of the exogenous agonist in a similar manner in the receptor saturation assay as in the calcium assay, strongly supporting the validity of using the calcium functional assay for measuring receptor mutant effects on ligand binding. This study has identified for the first time that the transmembrane region of PAR 2 is crucial for receptor activation by the synthetic ligands described herein, as defined by ligand binding and by induction of intracellular calcium signaling (Fig. 10) . In particular, four transmembrane mutations (Y82A, Y296A, N304A and N304L) reduced potencies of all three agonists examined here and highlighted the importance of those residues in PAR 2 activation. Furthermore, we examined 28 mutations of PAR 2 and found a cluster of residues defining a 'hot spot' within the TM regions of the receptor that is critical for PAR 2 -mediated signal transduction by these ligands, potentially due to changes in ligand-receptor interactions. Eight TM mutants (Y82, F155, Y156, F251, Y296, N304, Y311 and Y326) affected both of the two synthetic agonists similarly. Three of these residues (Y82, Y156 and Y326), along with ECL2 residue D228, were the most important for PAR 2 activation (>100 fold) induced by GB110 and 2f-LIGRLO-NH 2 . It is interesting to note that these two synthetic agonists did not give entirely identical responses, with two mutations (V250 and L307) showing significant differences between the effects of these agonists. This is the first time that PAR 2 has been mutated at multiple positions within and around its transmembrane helices. There have only been a few previous reports [15, 16, 42] of PAR 2 mutations which focused on one or a few mutations in ECL2 but not within the TM helices. The findings here of the importance of TM helices to ligand-induced activation, as measured by Caregions 2+ release, are novel and demonstrate a significant role of the TM regions in PAR 2 activation and downstream signal transduction. This study has also established that PAR 2 signaling is similar to other class A GPCRs, where TM regions have been shown to be crucial for interaction with agonists and antagonists [61, 10, 52] with strong support from crystal structures and computer models [22, 46] .
In this study, binding predictions were derived from a PAR 2 homology model built from the original rhodopsin class A GPCR crystal structure and later verified in two more recent class A GPCR crystal structures for ORL-1 (PDB: 4EA3) [60] and PAR 1 (PDB: 3VW7) [67] . The ligands described herein were re-docked into new homology models subsequently built [71] from these crystal structures. The PAR 1 -derived PAR 2 model was problematic (despite high sequence similarity) because the bound ligand vorapaxar is large and believed to distort the structure of PAR 1 . Vorapaxar does not bind to PAR 2 , so the high sequence identity of PAR 1 and PAR 2 created a problem with an unusual ligand-binding site being created for PAR 2 . Nonetheless, the predictions of the binding modes in both of these two additional models encouragingly overlapped with 40% of the residues predicted from the rhodopsin-based model, including almost all of the key residues.
There have been concerns that using rhodopsin-based model may bias toward an internal TM binding site, as the rhodopsin receptor itself has a covalently bound internal ligand. Although it is possible that the docking results from our model have been influenced by this, recent class A GPCRs have also been shown to share a common TM binding location as to that in rhodopsin [17] , suggesting an internal binding pocket is not unique to rhodopsin, but common among class A GPCRs. This was evidenced further by a recent crystal structure of CCR5 bound to its allosteric inhibitor maraviroc [59] . Furthermore, the rhodopsin template has been successfully used for homology modeling of other GPCRs, such as leukotriene receptor [23] , alpha1A receptor [25] , beta2 adrenoceptor [18] , MT1 and MT2 receptors [26] . It is important to note that there are limitations with homology structures derived from structures with low sequence homology, which has encouraged the development of GPCR models from different crystal structures. However, while it has been reported that there is no correlation between sequence identity and model quality [51] , the use of three PAR 2 homology models in our study which were derived from three different GPCR crystal structures strengthens our finding of a conserved subset of PAR 2 residues required for agonist-induced signaling. The identification of this subset of residues warranted further functional testing and validation by mutagenesis and signaling assays.
Our data has shown that PAR 2 activation by two synthetic agonists (2f-LIGRLO-NH 2 , GB110) was mainly affected by PAR 2 mutations clustered within the TM helices, whereas receptor activation by trypsin was largely unaffected by these mutations. Most mutations on GPCRs alter ligand activity either (i) directly by altering the specific binding site of the ligand or (ii) indirectly by changing receptor conformation with a knock-on or induced fit influence on ligand-receptor interaction. While results of this study alone cannot precisely unravel the mechanisms of PAR 2 activation, it is clear that the synthetic agonists examined were significantly more susceptible than trypsin to these changes in the TM helices of PAR 2 . In our opinion, the finding that over 20 amino acids clustered in the TM helices of PAR 2 strongly influence the actions of three synthetic ligands, but not the trypsin-induced native ligand, is suggestive of different ligand-binding sites on PAR 2 . While this 'hot spot' within PAR 2 is possibly an allosteric, rather than orthosteric, ligand-binding site, further studies and indeed PAR 2 crystal structures may be needed to confirm this hypothesis.
This study has involved a diverse set of PAR 2 mutations to probe the differential effects of a small group of synthetic ligands on PAR 2 -induced calcium release and identifies a receptor 'hot spot' within the TM regions of the receptor that is critical for PAR 2 -mediated calcium release by these ligands. Further sets of mutants in the ECL regions and the TM-solvent interface could similarly be used to (Table 1) are colored in red (>100 fold), blue (>15 fold) and yellow (<15 fold). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) identify residues important for different tethered ligands, known to be exposed by the actions of different endogenous proteases (e.g. trypsin, tryptase, factor VIIa, cathepsin S, elastase, etc). There have been a few other small molecule agonists (e.g. AC-55541, AC-264613 [54] ) and antagonists (e.g. ENMD-1068 [35] , K14585 [34, 45] , C391 [12] ) reported to modulate PAR 2 in recent years, as well as many proteases and peptides [30, 70] , including some peptides with lipid appendages (e.g. P2pal-18S [55] , 2at-LIGRL-PEG 3 -hdc [27] ). It is not known where any of these compounds bind on PAR 2 and so studies like that reported here could reveal similar or new receptor 'hot spots' required for ligand-induced PAR 2 signaling.
An additional level of complexity lies in a downstream signaling pathway being monitored for such studies. Recent identification of biased ligands for PAR 2 [48, 58, 70] suggests that different signaling pathways may be subtly influenced by only small changes to ligands, which in turn alter interactions with the receptor. Other studies have shown that mutations in the tethered ligand region of PAR 2 can differentially activate different signaling pathways (e.g. Ca 2+ , MAPK) [49, 24] , different proteases can induce different signaling profiles [24, 69, 70] , different small molecule ligands can bias signaling to different outcomes [28, 30] , and different cell types and reporter assays can produce different PAR 2 signaling. Linking these effects to specific residues in the receptor and specific components of the ligand, as we have begun to do in this study, can dramatically help improve our understanding of the molecular basis of PAR 2 -directed intracellular signaling and may permit development of drugs that control different PAR 2 -mediated signaling pathways in different physiological and disease settings. This is important because PAR 2 (like other GPCRs) has beneficial and protective physiological effects that may need to be preserved, while selectively modulating just one or a subset of PAR 2 -mediated signaling pathways associated with a particular diseased state may be more desirable. Studies such as this contribute to our understanding of ligand-induced PAR 2 signaling, while future studies are needed to determine the direct mechanisms employed for activation versus inhibition of different signaling pathways mediated by the same receptor and different (or even the same) ligands.
Conflicts of interest
JYS, JL, MKY and DPF are named inventors on several patent applications involving PAR 2 agonists and antagonists owned by the University of Queensland. No other competing interests.
Author contributions
JYS, MNA, WX, JDH and DPF wrote the manuscript; WX, PKM created the computer models; MNA, YH and JDH developed the PAR 2 mutants; MKY synthesed all the compounds; JYS, MNA, JL and AJC performed all of the cell experiments.
